Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-1815-2025

Apo B Reagent, REF: OSR6143 Recall

Apo B Reagent, REF: OSR6143

FDA recall Class III

Ongoing

FDA lists this Class III recall for Apo B Reagent, REF: OSR6143. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-1815-2025
Recall classification
Class III
Enforcement status
Ongoing
Initiation date
Apr 23, 2025
FDA report date
Jun 4, 2025
Quantity in commerce
2747 units
Distribution
See key details
FDA cause
Error in labeling

What is being recalled?

Apo B Reagent, REF: OSR6143

Affected model & UDI checker

Search the exact identifiers published for Z-1815-2025.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
OSR6143Apo B Reagent, REF: OSR6143Check source noticeNot specified
Not specifiedApo B Reagent, REF: OSR6143Check source notice15099590010409
FDA code information

Lot # 2631/UDI: 15099590010409

View the original FDA recall notice

Why was this product recalled?

The product Value Assignment Sheet (VAS) is used in calibration of the device. An erroneous value was included in the VAS which has the potential to generate an incorrect APO B patient result which could exceed the total allowable error for the APO B assay (11.6%). The error results in results with a positive bias up to 42%. However, based on the mitigating factors the risk to health is considered to be negligible or limited.

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did Beckman Coulter Ireland, Inc. take?

On April 23, 2025, Beckman Coulter issued a "Urgent Medical Device Recall" Notification to affected consignees via mail and E-Mail. Beckman Coulter asked consignees to take the following actions: 1. If your laboratory is reporting Apo B results generated using the combination of reagent OSR6143, Lot 2631 and calibrator ODR3022, Lot 3000 in mg/dL units, a retrospective review of patient results greater than 77 mg/dL and less than 176 mg/dL is recommended. 2. Discard the value assignment sheet located within each kit of Apo B OSR6143 Lot 2631. 3 Download the updated VAS kit insert from the Beckman Coulter website by searching LOSR6143_2631_ML.02. Beckman Coulter Diagnostics | Beckman Coulter. 4. Ensure that the level 4 calibrator ODR3022, Lot 3000 target value used for calibration of Apo B OSR6143 Lot 2631 is 116 mg/dL and aligns with the corrected VAS. 5. Please share this information with your laboratory staff and retain this notification as part of your laboratory Quality System documentation. If you have forwarded any of the affected product(s) listed above to another laboratory, please provide them a copy of this letter.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology